Company Disclosures › Sub-category

Legal Dispute

1 article

Tenax Up 3.8% on Phase 3 Data

Tenax Therapeutics shares rose 3.8% in pre‑market after presenting favorable Phase 3 LEVEL trial data for oral levosimendan at the ESC Congress. Snap Inc. gained 4.1% to $5.65 as it recovered from a 9